Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2HER-2 Gene Amplification 1

Interventions

Cyclophosphamide 627pembrolizumab 506Paclitaxel 455Gemcitabine 439Carboplatin 438Cisplatin 421Radiotherapy 382fludarabine 368Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 246Fluorouracil 229Dexamethasone 225Specimen Handling 224Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Biopsy 198Temozolomide 197Ipilimumab 197fludarabine phosphate 195Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Injections 171Cetuximab 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × MM-111 × Clear all
NCT01304784 2015-12-16

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
100 enrolled

HER-2 Gene Amplification

NCT00911898 2015-01-13

Monotherapy

Merrimack Pharmaceuticals

Phase 1 Completed
20 enrolled 5 charts
Breast

Breast Neoplasms

NCT01097460 2015-01-07

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Merrimack Pharmaceuticals

Phase 1 Completed
16 enrolled 7 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡